Granza Bio
Granza Bio is turning the natural attack particles that killer immune cells fire at their targets into programmable medicines that can re-arm exhausted immune cells against cancer.
Overview
Granza Bio builds on the discovery of supramolecular attack particles, the cytotoxic granules that cytotoxic T cells and natural killer cells release to kill targets, and engineers them into programmable therapeutics that deliver potent, localised killing and re-arm exhausted immune cells, with applications from cancer to autoimmunity. The company is an Oxford-linked spin-out based in San Francisco and is preclinical; no sourced financing rounds are recorded.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanySynsoryBio
Shares Cytokines & engineered cytokines, Y Combinator and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyLiyfe
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyREPROSENT
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.